LONDON: Johnson & Johnson’s talks to acquire Swiss drugmaker Actelion Ltd are progressing after the world’s biggest health-care products maker raised its offer, people with knowledge of the matter said.
Actelion rejected an initial proposal - valued at about US$246 a share (249 Swiss francs) - prompting J&J to raise the bid to more than US$250 per share, said one of the people, who asked not to be identified because the information is private.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!